PharmTech Drug Digest 11.20
|Articles|October 2, 2014

Explore state-of-the-art clinical filling in Chicago

Author(s)Vetter Pharma

Parenteral drug development is complex, costly, and subject to many levels of risk during the clinical phases. Only a few drug products ever make it to phase III, through approval, and on into commercial manufacturing. Given the numerous hurdles that exist, realizing the drug development process efficiently during all phases has become ever more important. And, having the right partner on board to support the project is critical in preparing a valuable drug package that can be used for either further product development and commercialization, or for a successful out-licensing deal.

Explore state-of-the-art clinical filling in Chicago

Parenteral drug development is complex, costly, and subject to many levels of risk during the clinical phases. Only a few drug products ever make it to phase III, through approval, and on into commercial manufacturing. Given the numerous hurdles that exist, realizing the drug development process efficiently during all phases has become ever more important. And, having the right partner on board to support the project is critical in preparing a valuable drug package that can be used for either further product development and commercialization, or for a successful out-licensing deal.

The podcast will showcase Vetter´s service portfolio as a company in general, and its offering in the development service area in detail. In addition, this podcast will focus on the companies` capabilities in its Chicago development service site, including its customer base. An informative case study highlighting the critical expertise needed in today´s drug development environment will be presented.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.